Memgen's ISF35 Sensitizes Cancer Cells to Chemotherapy
DALLAS, TX (Dec 8, 2009) - Memgen announced today that positive data evaluating its active cellular immunotherapy product, ISF35, in combination with chemotherapy in resistant chronic lymphocytic leukemia (CLL) were presented December 7 during the 51st Annual Meeting of the American Society of Hematology.
The ongoing phase Ib trial's first two patients have both achieved minimal residual disease-negative (MRD-) complete responses, according to Januario Castro, M.D., Associate Clinical Professor, Bone Marrow Transplant Division of the University of California, San Diego (UCSD).
"These are very encouraging results, especially in the setting of patients with high risk CLL," said Dr. Castro. "If our preliminary results are confirmed this new therapy could be a breakthrough for patients with refractory and 17p-deleted CLL."
Memgen is a clinical stage biotechnology company dedicated to improving overall survival in cancer patients. Its technology platform is based on discoveries by leaders in the field of hematologic malignancies. Memgen is developing truly effective and non-toxic targeted therapies utilizing key elements of the human immune system engineered to generate anti-cancer immune responses. Learn more
Latest News & Events ::
12/1/2009 - Memgen's Clinical Trial Results of ISF35 for Chronic Lymphocytic Leukemia Selected for Presentation at ASH 2009 Annual Meeting
Results from a recent clinical trial of ISF35 will be presented at the annual meeting of the American Society of Hematology (ASH) on December 7 in New Orleans.
6/4/2009 - Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic Leukemia
An ongoing Phase Ib study of Memgen's cancer immune therapy, ISF35, has produced positive results, including a complete remission.